Co-Authors
This is a "connection" page, showing publications co-authored by FREDERICK LANG and ELIZABETH SHPALL.
Connection Strength
0.880
-
Development of a rabbit human glioblastoma model for testing of endovascular selective intra-arterial infusion (ESIA) of novel stem cell-based therapeutics. Neuro Oncol. 2024 01 05; 26(1):127-136.
Score: 0.238
-
Characterization of patient-derived bone marrow human mesenchymal stem cells as oncolytic virus carriers for the treatment of glioblastoma. J Neurosurg. 2022 Mar 01; 136(3):757-767.
Score: 0.202
-
RNAi technology targeting the FGFR3-TACC3 fusion breakpoint: an opportunity for precision medicine. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa132.
Score: 0.190
-
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. Cancer Cell. 2024 Aug 12; 42(8):1450-1466.e11.
Score: 0.062
-
Targeting the av integrin/TGF-? axis improves natural killer cell function against glioblastoma stem cells. J Clin Invest. 2021 07 15; 131(14).
Score: 0.050
-
Endovascular Selective Intra-Arterial Infusion of Mesenchymal Stem Cells Loaded With Delta-24 in a Canine Model. Neurosurgery. 2020 12 15; 88(1):E102-E113.
Score: 0.048
-
Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. Clin Cancer Res. 2020 07 15; 26(14):3565-3577.
Score: 0.046
-
Microcatheter delivery of neurotherapeutics: compatibility with mesenchymal stem cells. J Neurosurg. 2020 10 01; 133(4):1182-1190.
Score: 0.044